Specifically, we aimed to examine the relationships between these apolipoprotein levels and psoriasis severity, as measured by the Psoriasis Area and Severity Index (PASI), as well as disease duration and associated systemic inflammation, assessed by serum C-reactive protein (CRP) levels. The gene discussed is CRP; the disease is psoriasis.